A Phase 2 interventional study of Fixed-Combination Bimatoprost/Brimonidine and Bimatoprost Ophthalmic Solution 0.01% in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-01-26.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Glaucoma by AbbVie — none open to participants now, none under way, none of them phase 3. Glaucoma · AbbVie.
Among the 34 studies in Glaucoma by AbbVie, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2013, is one of 4 in phase 2, and was the 25th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 34 studies in Glaucoma by AbbVie is open now. The open studies under Glaucoma, anywhere →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 13 · Phase 4 12
First in 2002; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 158 across the 31 interventional studies, 59 across the 3 observational. Of the 33 that completed or were terminated, 23 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Glaucoma by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
Drug: Fixed-Combination Bimatoprost/Brimonidine
One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
Drug: Bimatoprost Ophthalmic Solution 0.01% · Drug: Vehicle Ophthalmic Solution
One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
Drug: Brimonidine Tartrate Ophthalmic Solution 0.2%
One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
Also known as: LUMIGAN
One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
Also known as: ALPHAGAN
Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).
Time frame: Baseline, Day 42
Change From Baseline in Average Eye Mean Diurnal IOP
IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).
Time frame: Baseline, Day 14, Day 28
Average Eye Mean Diurnal IOP
IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12.
Time frame: Day 14, Day 28, Day 42
| Milestone | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% |
|---|---|---|---|
| Started | 38 | 36 | 38 |
| Completed | 38 | 36 | 37 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).
| Millimeters of Mercury (mmHg) | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% |
|---|---|---|---|
| Baseline | 24.54 ± 1.712 | 24.38 ± 2.022 | 24.29 ± 1.457 |
| Change from Baseline at Day 42 (N=38, 36, 37) | -6.79 ± 2.277 | -6.63 ± 2.284 | -3.92 ± 2.574 |
IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).
| mmHg | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% |
|---|---|---|---|
| Baseline | 24.54 ± 1.712 | 24.38 ± 2.022 | 24.29 ± 1.457 |
| Change from Baseline at Day 14 | -7.63 ± 2.152 | -6.79 ± 1.997 | -4.67 ± 2.944 |
| Change from Baseline at Day 28 | -7.25 ± 2.328 | -6.98 ± 2.260 | -4.22 ± 2.869 |
IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12.
| mmHg | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% |
|---|---|---|---|
| Day 14 | 16.91 ± 2.004 | 17.59 ± 2.363 | 19.61 ± 2.572 |
| Day 28 | 17.29 ± 2.588 | 17.40 ± 2.549 | 20.06 ± 2.540 |
| Day 42 (N=38, 36, 37) | 17.75 ± 2.505 | 17.76 ± 2.467 | 20.34 ± 2.218 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fixed-Combination Bimatoprost/Brimonidine | — | 0/38 (0%) | 27/38 (71.1%) |
| Bimatoprost Ophthalmic Solution 0.01% and Vehicle | — | 1/36 (2.8%) | 25/36 (69.4%) |
| Brimonidine Tartrate Ophthalmic Solution 0.2% | — | 1/38 (2.6%) | 20/38 (52.6%) |
| Event | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% |
|---|---|---|---|
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/38 | 1/36 | 0/38 |
| Acute Myocardial InfarctionCardiac disorders | 0/38 | 0/36 | 1/38 |
| Event | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% |
|---|---|---|---|
| Conjunctival HyperaemiaEye disorders | 18/38 | 16/36 | 2/38 |
| Eye PruritusEye disorders | 5/38 | 5/36 | 3/38 |
| Punctate KeratitisEye disorders | 2/38 | 4/36 | 2/38 |
| Dry MouthGastrointestinal disorders | 0/38 | 1/36 | 4/38 |
| Eye IrritationEye disorders | 0/38 | 3/36 | 1/38 |
| Eye DischargeEye disorders | 3/38 | 1/36 | 1/38 |
| BlepharospasmEye disorders | 3/38 | 0/36 | 0/38 |
| NasopharyngitisInfections and infestations | 0/38 | 2/36 | 0/38 |
| Eye PainEye disorders | 2/38 | 1/36 | 2/38 |
| Instillation Site PruritusGeneral disorders | 2/38 | 1/36 | 0/38 |
| Age, Customized(Participants) | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% | Total |
|---|---|---|---|---|
| <45 years | 1 | 0 | 0 | 1 |
| Between 45 and 65 years | 21 | 14 | 20 | 55 |
| >65 years | 16 | 22 | 18 | 56 |
| Sex: Female, Male(Participants) | Fixed-Combination Bimatoprost/Brimonidine | Bimatoprost Ophthalmic Solution 0.01% and Vehicle | Brimonidine Tartrate Ophthalmic Solution 0.2% | Total |
|---|---|---|---|---|
| Female | 20 | 22 | 25 | 67 |
| Male | 18 | 14 | 13 | 45 |
The record gives a start of Jun 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.